Review anchor
HL-60
CELL-LINE · Homo sapiens
As of 2026-09-14
Evidence Snapshot
HL-60
CHEMBL383
CELL-LINE
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats HL-60 as ChEMBL target CHEMBL383. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL383
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why HL-60 matters
HL-60 is reviewed as HL-60; the current evidence base includes 102 approved drugs, 54926 compounds, and 6806 assays, with lead potency reaching pChEMBL 10.9.
Protein context
HL-60
HL-60
Review this target as HL-60.
Protein source · UniProt accession via ChEMBL component mappingDisease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 102 approved drugs, 54926 compounds, and 6806 assays for this target. The dominant activity type is IC50. CHEMBL2158589 is the current potency anchor at pChEMBL 10.9.
Use CHEMBL2158589 as the tractability anchor when discussing potency (pChEMBL 10.9).
Activity source · ChEMBL 36 via Core Engine
102 approved
pChEMBL 10.9
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why HL-60 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
54926
Total Compounds
6806
Total Assays
102
Approved Drugs
IC50: 15062.0, KI: 17.0, EC50: 656.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL2158589
|
10.9 | IC50 | — |
|
|
No preferred name
CHEMBL220846
|
10.7 | EC50 | — |
|
|
No preferred name
CHEMBL1254818
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL58
|
10.6 | IC50 | Approved |
|
|
No preferred name
CHEMBL2158588
|
10.6 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
QUIZARTINIB
CHEMBL576982
|
2023 |
|
|
PACRITINIB
CHEMBL2035187
|
2022 |
|
|
SELUMETINIB
CHEMBL1614701
|
2020 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
VENETOCLAX
CHEMBL3137309
|
2016 |
|
|
PALBOCICLIB
CHEMBL189963
|
2015 |
|
|
IDELALISIB
CHEMBL2216870
|
2014 |
|
|
TRAMETINIB
CHEMBL2103875
|
2013 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
|
|
OMACETAXINE MEPESUCCINATE
CHEMBL46286
|
2009 |
|
|
TEMSIROLIMUS
CHEMBL1201182
|
2007 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |
|
|
VORINOSTAT
CHEMBL98
|
2006 |
|
|
SORAFENIB
CHEMBL1336
|
2005 |
|
|
CLOFARABINE
CHEMBL1750
|
2004 |
|
|
TEMOPORFIN
CHEMBL500576
|
2001 |
|
|
ALITRETINOIN
CHEMBL705
|
1999 |
|
|
PARICALCITOL
CHEMBL1200622
|
1998 |
|
|
TOPOTECAN
CHEMBL84
|
1996 |
|
|
GEMCITABINE
CHEMBL888
|
1996 |
|
|
IRINOTECAN
CHEMBL481
|
1996 |
|
|
DOCETAXEL ANHYDROUS
CHEMBL92
|
1995 |
|
|
DOCETAXEL
CHEMBL3545252
|
1995 |
|
|
VINORELBINE
CHEMBL553025
|
1994 |
|
|
PACLITAXEL
CHEMBL428647
|
1992 |
|
|
FLUDARABINE PHOSPHATE
CHEMBL1096882
|
1991 |
|
|
MITOXANTRONE
CHEMBL58
|
1987 |
|
|
AMSACRINE
CHEMBL43
|
1987 |
|
|
MITOXANTRONE HYDROCHLORIDE
CHEMBL1417019
|
1987 |
|
|
ASCORBIC ACID
CHEMBL196
|
1985 |
|
|
ETOPOSIDE
CHEMBL44657
|
1983 |
|
|
NICLOSAMIDE
CHEMBL1448
|
1982 |
|
|
MITOMYCIN
CHEMBL105
|
1981 |
|
|
DAUNORUBICIN
CHEMBL178
|
1979 |
|
|
DAUNORUBICIN HYDROCHLORIDE
CHEMBL1563
|
1979 |
|
|
CALCITRIOL
CHEMBL846
|
1978 |
|
|
DOXORUBICIN
CHEMBL53463
|
1974 |
|
|
DOXORUBICIN HYDROCHLORIDE
CHEMBL359744
|
1974 |
|
|
MICONAZOLE
CHEMBL91
|
1974 |
|
|
TRETINOIN
CHEMBL38
|
1971 |
|
|
FLOXURIDINE
CHEMBL917
|
1970 |
|
|
CYTARABINE
CHEMBL803
|
1969 |
|
|
VINBLASTINE
CHEMBL159
|
1965 |
|
|
DACTINOMYCIN
CHEMBL1554
|
1964 |
|
|
VINCRISTINE
CHEMBL90555
|
1963 |
|
|
FLUOROURACIL
CHEMBL185
|
1962 |
|
|
COLCHICINE
CHEMBL107
|
1961 |
|
|
PREDNISOLONE
CHEMBL131
|
1955 |
|
|
METHOXSALEN
CHEMBL416
|
1954 |
|
|
METHOTREXATE
CHEMBL34259
|
1953 |
Source Header